El cáncer de pulmón representa una de las principales causas de mortalidad por cáncer a nivel mundial. Cada año se diagnostican 2.2 millones de nuevos casos, cuyo pronóstico depende de cómo de t...
Read more
The IRB Barcelona spin-off Gate2Brain has reached a major milestone in the fight against pediatric brain tumors by obtaining Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for ...
Read more
Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announced the successful closing of an oversubscribed $1...
Read more
Sanitas, compañía especialista en el cuidado de la salud, Gutinver y otros inversores privados se han asociado en el terreno de la investigación y entran como accionistas en el proyecto MIMO Biosci...
Read more
Oryzon Genomics announced today that the Russian Patent Office has issued a “Decision to grant” communication for Oryzon’s Russian patent application RU2021130172. This patent relates to vafidem...
Read more
VIVEbiotech provides process development, manufacturing and analytical testing for leading biopharmaceutical companies engaged in gene therapy and cell therapy projects. With a specific focus on lenti...
Read more
A group of purification specialists in a small town in western Slovenia develops innovative technologies that separate right from wrong fast and efficiently – making sure patients worldwide receive ...
Read more
Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European spe...
Read more
SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
Read more
Esta colaboración fortalecerá un proyecto innovador surgido en la Universidad de Santiago, centrado en la regulación de los mecanismos cerebrales que intervienen en el metabolismo y que pueden vers...
Read more
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 s...
Read more
It has been developed a new therapy based on nanotechnology called nanoGLA for the treatment of Fabry disease. The new therapeutic solution has shown remarkable efficacy in preclinical studies
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
